e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Pulmonary fibrosis: mechanisms of disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction
michael katovich (Gainesville, United States of America), Anandharajan Rathinasabapathy, Alana Horowitz, Kelsey Horton, Ulrike Steckelings, Thomas Unger, Colin Sumners, Mohan Raizada, Vinayak Shenoy, Michael Katovich
Source:
International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Session:
Pulmonary fibrosis: mechanisms of disease
Session type:
Thematic Poster Session
Number:
926
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
michael katovich (Gainesville, United States of America), Anandharajan Rathinasabapathy, Alana Horowitz, Kelsey Horton, Ulrike Steckelings, Thomas Unger, Colin Sumners, Mohan Raizada, Vinayak Shenoy, Michael Katovich. C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction. Eur Respir J 2015; 46: Suppl. 59, 926
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Blocking endothelin: breaking new ground
Source: Eur Respir Rev 2008; 17: 24-29
Year: 2007
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice
Source: Eur Respir J 2005; 25: 708-714
Year: 2005
Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
The effects of angiotensin II and related peptides on intracellular Ca2+ release in human lung fibroblasts
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
The increased contractility of idiopathic pulmonary fibrosis lung fibroblasts is dependent on angiotensin signalling
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan)
Source: Eur Respir J 2007; 30: Suppl. 51, 120s
Year: 2007
Evaluation in administration of angiotensin II receptor antagonist Valsartan in the treatment of hypertension patients with chronic obstructive pulmonary disease.
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice
Source: Eur Respir J 2008; 32: 426-436
Year: 2008
Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009
Pulmonary hypertension in COPD
Source: Eur Respir Mon 2013; 59: 189-205
Year: 2013
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Effects of a TRPV4 antagonist and pirfenidone on idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats
Source: Eur Respir J 2010; 35: 904-912
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept